No evidence to support use of vitamin C supplementation in cancer
the ONA take:
According to a new study published in the journal The Oncologist, researchers have found that there is no high-quality evidence to support the use of ascorbate (vitamin C) supplementation to enhance efficacy or reduce toxicity of chemotherapy in patients with cancer.
For the systematic review, researchers from the Ottawa Hospital Cancer Centre Division of Medical Oncology in Ottawa, Ontario, Canada, sought to investigate whether supplemental ascorbate synergizes the anticancer effects of chemotherapy and reduces its toxicity.
Researchers identified 34 articles to be included in the study from Medline, EMBASE, and the Cochrane central register. Among those, there were five randomized controlled studies, 12 phase 1/2 studies, six observational trials, and 11 case reports.
The studies included a total of over 8,000 patients. Results showed no statistically significant improvements in overall survival or progression-free survival or reduced toxicity with supplemental ascorbate use compared with the control arm.
The authors note that high-quality placebo-controlled studies are needed to assess the effects of ascorbate on chemotherapy efficacy and toxicity in patients with cancer.
No high-quality evidence to support the use of ascorbate (vitamin C) supplementation to enhance cancer treatment.
Sign Up for Free e-newsletters
- Leukemia Risk in Children, Maternal Use of Hormonal Contraception Linked in Population Study
- Molecular Features May Predict Response in Primary Pancreatic Cancer
- Medication, Vaccination Uptake Improved by Involving Pharmacists in Elder Cancer Care
- Commission Seeks Standardized Adverse Event Assessments in Hematologic Malignancies
- Chemoimmunotherapy prolongs PFS in metastatic triple-negative breast cancer
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Use of Corticosteroids With PD-1 or PD-L1 Inhibitors Associated With Poorer Outcomes in NSCLC
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Counseling Patients on Oral Chemotherapy
- Patients and Caregivers Worry About Cost of Cancer Care
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Head and Neck Cancer Survivors Have Increased Suicide Risk
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|